article
Long-Term Treatment with a Staphylococcus Toxoid Vaccine in Patients with Fibromyalgia and Chronic Fatigue Syndrome
Journal: Journal of Chronic Fatigue Syndrome, Volume: 13 Issue: 4,
Page Range: 29 - 40 (2006) Pub Date: 4/5/2007
Authors:
Carl-Gerhard Gottfries MD, PhD
Ove Häger, Research Nurse
Björn Regland MD, PhD
Olof Zachrisson MD, PhD,
One hundred and sixty patients with fibromyalgia and chronic fatigue
syndrome, who were on a continuous treatment with a Staphylococcus
vaccine, were followed during one year with repeated consultation
visits. The patients had participated in controlled studies and been
on continuous treatment with the vaccine for 22 ±10 months before
inclusion into this follow-up study.
They were treated with 1 mL of the vaccine subcutaneously every
third to fourth week. Adverse events were few. The adherence to the
treatment was very good. Over a period of one year, 8% withdrew, and
in only 5%, the withdrawal was due to insufficient clinical effect.
Only in two cases where the patients were allergic to the
preservative of the vaccine, the side effects caused the withdrawal
of the treatment. Ratings with scales (CPRS-15 and FibroFatigue)
showed improvement from start of treatment and also further
improvement during the follow-up year.
In view of the natural history for these disorders the result is of interest.
Journal: Journal of Chronic Fatigue Syndrome, Volume: 13 Issue: 4,
Page Range: 29 - 40 (2006) Pub Date: 4/5/2007
Authors:
Carl-Gerhard Gottfries MD, PhD
Ove Häger, Research Nurse
Björn Regland MD, PhD
Olof Zachrisson MD, PhD,
One hundred and sixty patients with fibromyalgia and chronic fatigue
syndrome, who were on a continuous treatment with a Staphylococcus
vaccine, were followed during one year with repeated consultation
visits. The patients had participated in controlled studies and been
on continuous treatment with the vaccine for 22 ±10 months before
inclusion into this follow-up study.
They were treated with 1 mL of the vaccine subcutaneously every
third to fourth week. Adverse events were few. The adherence to the
treatment was very good. Over a period of one year, 8% withdrew, and
in only 5%, the withdrawal was due to insufficient clinical effect.
Only in two cases where the patients were allergic to the
preservative of the vaccine, the side effects caused the withdrawal
of the treatment. Ratings with scales (CPRS-15 and FibroFatigue)
showed improvement from start of treatment and also further
improvement during the follow-up year.
In view of the natural history for these disorders the result is of interest.